GlassScriptPhysician profile
Allison Butler
NPI 1043989577
$3,858.64
in general payments reported to CMS, 2019-2025
24 companies · $46.80 in 2025
The $46.80 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.00 · 2022: $764 · 2023: $1,081 · 2024: $1,944 · 2025: $46.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,004 · Education: $67.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.55 |
| Education | $67.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $808.56 | 2022-2024 | |
| Novo Nordisk INC | $692.06 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $424.83 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $259.71 | 2022-2024 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $254.55 | 2022-2024 | |
| Exact Sciences Corporation | $208.18 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $160.32 | 2023-2024 | Veozah |
| Pfizer INC. | $160.15 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $146.99 | 2024 | Voquezna |
| Dexcom, INC. | $121.10 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.55 | 2022-2023 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $104.82 | 2023-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $79.53 | 2023-2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $64.31 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $53.42 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.01 | 2022-2024 | Repatha, Otezla |
| Cranial Technologies, INC | $31.23 | 2022-2024 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $28.71 | 2022 | |
| Xeris Pharmaceuticals, INC. | $28.18 | 2024 | Gvoke Hypopen |
| Sunovion Pharmaceuticals INC. | $19.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.85 | 2023 | Trintellix |
| Esperion Therapeutics, INC. | $17.19 | 2024 | Nexletol |
| Merck Sharp & Dohme LLC | $15.15 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Glaxosmithkline, LLC. | $13.68 | 2023 | Shingrix, Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.